Predicting target lesion failure following percutaneous coronary intervention through machine learning risk assessment models

European Heart Journal - Digital Health

31 August 2023
Organised by: Logo
ESC Journals CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE Acute Coronary Syndromes Interventional Cardiology

Abstract

AbstractAims

Central to the practice of precision medicine in percutaneous coronary intervention (PCI) is a risk-stratification tool to predict outcomes following the procedure. This study is intended to assess machine learning (ML)-based risk models to predict clinically relevant outcomes in PCI and to support individualized clinical decision-making in this setting.

Methods and results

Five different ML models [gradient boosting classifier (GBC), linear discrimination analysis, Naïve Bayes, logistic regression, and K-nearest neighbours algorithm) for the prediction of 1-year target lesion failure (TLF) were trained on an extensive data set of 35 389 patients undergoing PCI and enrolled in the global, all-comers e-ULTIMASTER registry. The data set was split into a training (80%) and a test set (20%). Twenty-three patient and procedural characteristics were used as predictive variables. The models were compared for discrimination according to the area under the receiver operating characteristic curve (AUC) and for calibration. The GBC model showed the best discriminative ability with an AUC of 0.72 (95% confidence interval 0.69–0.75) for 1-year TLF on the test set. The discriminative ability of the GBC model for the components of TLF was highest for cardiac death with an AUC of 0.82, followed by target vessel myocardial infarction with an AUC of 0.75 and clinically driven target lesion revascularization with an AUC of 0.68. The calibration was fair until the highest risk deciles showed an underestimation of the risk.

Conclusion

Machine learning–derived predictive models provide a reasonably accurate prediction of 1-year TLF in patients undergoing PCI. A prospective evaluation of the predictive score is warranted.

Registration

Clinicaltrial.gov identifier is NCT02188355.

Contributors

Mamas A Mamas
Mamas A Mamas

Author

Keele University Keele , United Kingdom of Great Britain & Northern Ireland

Marco Roffi
Marco Roffi

Author

University hospitals of Geneva Geneva , Switzerland

Alessandro Beneduce
Alessandro Beneduce

Author

IRCCS San Raffaele Scientific Institute Milan , Italy